Targeting TROP2: Datopotamab Deruxtecan (Dato-DXd) - Lung Cancer OncInsights 2025-26
Автор: Global Resource for Advancing Cancer Education
Загружено: 2025-12-17
Просмотров: 20
In this video series that was recorded in July, September and November of 2025, leading oncologists present patients and caregivers with the most current and emerging treatment information in lung cancer, delivered in a concise and easy-to-understand format.
In this video, Dr. Raez discusses datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate that was recently approved in June 2025 for previously treated, advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
View transcripts here: https://drive.google.com/file/d/1IdHh...
Thank you to our Sponsors! #janssen #genentech #lilly and Summit Therapeutics
Music: Ester - Here (BenSound)
License: 2242649
For more, please visit https://cancerGRACE.org/. To join the conversation or ask a question, visit https://cancergrace.org/forum.
To follow along with this video using the YouTube transcript, click Show Transcript at the bottom of the YouTube description. To translate that transcript into other languages while using chrome, right click and click on translate, click the three dots, and click 'Choose another language'. Find your chosen language in the dropdown list.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
